Announcement on Change of Sponsor Representative
Filed with SSE · · 2 pages · Chinese
Sichuan Huiyu Pharmaceutical Co. Ltd. on 6ix
Earlier from Sichuan Huiyu Pharmaceutical
- Announcement on Voluntary Disclosure of Notice of Acceptance for Drug Clinical Trial Obtained by HY07121 Injection (Subcutaneous Injection)
- Announcement on Implementation of Dividend Distribution for 2025
- Indicative Announcement on Change in Equity of Shareholders with Over 5% Shares Reaching 1% Scale
- Announcement on Progress in Providing Guarantees for Wholly-owned Subsidiaries
- Announcement on Election of Employee Representative Directors for the 3rd Board of Directors
Later from Sichuan Huiyu Pharmaceutical
- Announcement on Voluntary Disclosure of Obtaining Overseas Marketing Authorization for the Company's Product
- Announcement on Initially Granting Restricted Stocks to Incentive Objects of the 2026 Restricted Stock Incentive Plan
- Announcement on Voluntary Disclosure of HY-1016 Sustained-release Injection Obtaining Notice of Approval for Drug Clinical Trial
- Announcement on Voluntary Disclosure of Signing a Strategic Cooperation Agreement
- Announcement on Abnormal Fluctuations in Stock Trading
Follow Sichuan Huiyu Pharmaceutical into a list and get an email when it puts out news.
Follow Sichuan Huiyu Pharmaceutical